Speakers:
- Dr. Naoto Ueno, University of Hawaiʻi Cancer Center/ CancerX Co-founder, Co-representative director, Japan Team Oncology Program, Founder
- Dr. Kenichi Nakamura, Director, Department of International Clinical Development, National Cancer Center Hospital
- Prof. Folakemi Odedina, Professor and Enterprise Deputy Director for Community Outreach & Engagement, Mayo Clinic Comprehensive Cancer Center.
- Dr. Richard Pazdur, Director, Oncology Center of Excellence, Acting Director, Office of Hematology and Oncology Products, United States Food and Drug Administration
- Ms. Kaoriko Kuge (Moderator), Fujisankei Communications International, Inc.
*English below after Japanese
新しい治療の開発に必須の臨床試験。大規模な臨床試験は欧米主導であることが多く、臨床試験の参加者は自ずと欧米の患者が中心となる。こうした臨床試験で効果が確認された場合でも、人種の違いによる生物学的多様性を踏まえると、確認された効果がその他の地域の患者でも同様の効果が出るとは限らない。
臨床試験終了後に多様な国ですぐに導入できるようにするには、多様な国から臨床試験に参加する必要があるが、そういった環境を整えるには何が必要か、臨床試験を主導している米国の視点からPazdur先生、日本でアジア諸国からの臨床試験参画を促している中村先生、臨床試験においてマイノリティや社会的弱者に公平な機会を与えるために活動しているFolakemi先生、ハワイを含む太平洋島しょ地域で臨床試験を主導している上野先生を招き、議論を深める。
Session time:
2022.2.4 Sat. 10:45-11:45 am, JST
2022.2.3 Fri. 8:45-9:45 pm, EST / 3:45-4:45 pm, HST
CancerX aims to cross-fertilize our ideas and collaborate so that we can bring change and cross out cancer. X stands for collaboration, change, and cross-out.
CancerX General Incorporated Association hosts World Cancer Week 2023 as a platform to address cancer-related social issues. Based on the concept of “Collective Action!,” we host 21 sessions, including the CancerX Global.
Since 2019, CancerX has hosted events during World Cancer Day, one of the largest events in Japan that bring together speakers and participants from diverse perspectives around World Cancer Day on February 4 to discuss medical and social issues related to cancer.
For this year’s CancerX Global session, the focus is “Close the gap in the access to clinical trials for patients with cancer.” Clinical trials are essential for the development of new treatments. However, large-scale clinical trials are often led by western countries. Therefore, clinical trial participants are generally patients from the United States and European countries. Even if a therapeutic effect is confirmed in such clinical trials, the result may differ for patients in non-western regions, given the biological diversity due to racial differences. To introduce the treatments worldwide immediately after the completion of clinical trials, we need to be more inclusive to trial participants from various countries.
We will have a comprehensive, in-depth discussion to tackle DEI-based therapy development with Dr. Pazdur from the U.S. FDA perspective, Dr. Nakamura from Japan, who promotes clinical trial participation from Asian countries, Dr. Folakemi, who provides equitable opportunities for minorities and marginalized populations in Africa, and Dr. Ueno, who is leading clinical trials in the Hawai’i and US Affiliated Pacific Islands.This CancerX Global 2023 session will be open to the public (no registration needed and free). You can join the session by simpling clicking the following link here or the QR code.
